Analgesics - Global Strategic Business Report - Market Research Reports

Contents:

ANALGESICS
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.
1. Market Analysis II-1
Industry Overview II-1
Outlook II-1
Worldwide Analgesics Sales
By Region II-1
Worldwide Analgesics Sales
By Product/Group Segment II-1
Historic Review II-2

2. Global Analgesics Market Overview II-3
Growth Drivers II-3
Analgesics Market
Offering Immense Potential II-3
Internal Analgesics
Riding on a Crest II-3
Neuropathic Pain
The Virgin Sector Longing for Attention II-3
Ibuprofen Scoring High II-3
External Analgesics
In a slump II-3
Price
The All Important Factor II-4
Boom in Demand for Topical Analgesic Patches II-4

3. Product Overview II-5
A Brief History II-5
Analgesics II-5
Definition II-5
Acute Pain II-5
Chronic Pain II-6
Pain Therapeutic Market II-6
Drugs Combating Pain II-6
Local Anesthetics II-7
Narcotic Opioids II-7
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) II-7
Types of NSAIDS II-7
Common NSAIDs II-8
Clinical Use... II-9
Side Effects... II-9
Aspirin II-10
The Wonder Drug... II-10
Aspirin Also Reduces Risk of Pancreatic Cancer II-10
PolyAspirin: The Safer and More Potent Polymer Variant of
Aspirin II-10
Cardio-Protective Effects of Aspirin Hindered by Ibuprofen II-11
Mode of Action II-11
Contraindications II-11
Acetaminophen II-11
Acetaminophen Protects Heart Muscle II-12
Acetaminophen Reduces Incidence of Ovarian Cancer II-12
Side-effects of Acetaminophen Overdose II-12
Ibuprofen, Ketoprofen and Naproxen II-13
Combination Analgesics II-13
Table 1: Opioid Analgesics Market: Percentage Share of
Opioid/Acetaminophen Combination Products in the Opioid
Script Volume (includes corresponding Graph/Chart) II-13
OTC Analgesics: An Overview II-14

4. Industry Dynamics II-15
The Mega-Mergers... II-15
Major Pharma Mergers in Recent Past II-15
Escalating R&D Costs: A Boon or Bane? II-15
Timeline of the Drug Approval Process II-16
Lower Shares
A Fallout of Mergers II-16
“Superaspirins”: Revolutionizing the NSAIDs Market II-16
Cox-2 Inhibitors in for Some Trouble II-17
Celebrex: The Most Successful Pharmaceutical Launch II-17
Vioxx: Gained Market Share Despite a Late Start II-17
Clash of the Titans: Vioxx Vs. Celebrex II-18
Rx-to-OTC Switch II-18
Why Consumers Prefer OTC Drugs? II-18
Development of Analgesic Tripeptides II-18

5. Recent Clinical Trails
An Overview II-19
Australian Center for Blood Diseases Develops a Drug II-19
More Effective than Aspirin II-19
Aspirin Plays Active Role in Controlling Risk of Dementia and
Cancer II-19
Aspirin Aids in Controlling Cancer of Esophagus II-19
Aspirin Reduces the Risk of Mouth Cancer II-20
Aspirin Increasing the Risk of Strokes in Men II-20
UK Scientist Unearths the Mechanism of Acetylsalicylic Acid,
an active ingredient in Aspirin II-20
Aspirin Lowers Cardiovascular Risk Caused by Vioxx II-20

6. Product Innovations/Introductions II-21
Novartis Launches Voltarol Pain-Eze Emulgel . II-21
TheraQuest Launches TQ-1017 II-21
Mentholatum Company Introduces WellPatch Deep Heat Patch II-21
Product Innovations/Introductions in Recent Past II-21
SSP and Mepha Launch Olfen Patch in Switzerland II-21
W.F. Young Expands Absorbine Jr® II-21
Pfizer Unveils Neurontin II-22
Ligand Pharmaceuticals Introduces Avinza in the US II-22
AlphaRx Introduces Flexogan II-22
Essere Introduces Roll-On Analgesic II-22
Novartis Introduces Topical Analgesic and Cough Suppressant
in Sticks II-22
SSL International Introduces Easy-To-Swallow Version of Paramol II-22
Janssen Launches Duragesic, a Narcotic Analgesic II-22
Abbott Laboratories Launches Narcotic Analgesic II-23
Ortho-McNeil Launches Flexeril II-23
Elkins-Sinn Launches Opioid Analgesic II-23
FH Faulding Launches Narcotic Analgesic, Kadian II-23
ICN Pharmaceuticals Launches Opioid Aanalgesic, Levo Dromoran II-23
Amarin Launches Motofen, a Narcotic Analgesic and Anti-
Cholinergic II-23
Purdue Pharma Launches MS Contin, a Narcotic Analgesic II-23
Able Laboratories Unveils New Versions of Acetaminophen and
Hydrocodone Bitartrate II-23
Whitehall Launches Anadin Analgesic Tablets in South Africa II-23
Leiner Launches Ibuprofen Softgel Capsules II-24
Crookes Healthcare Launches Ibuprofen Singles for Children II-24
SSL International Launches Cuprofen Ibuprofen for Children II-24
Lloydspharmacy Launches Ibuprofen Suspension for Children II-24
Pharmasave Drugs Launches Acetaminophen Tablets II-24
Wendt Laboratories Introduces Aspirin 81 for Daily Use II-24
Reckitt Benckiser (India) Launches Disprin CV Branded 100 mg
Aspirin II-24
Moss Pharmacy Releases Aspirin Products for Consumers in the
United Kingdom II-25
Whitehall Laboratories Introduces Anadin Ultra Ibuprofen
Capsules in the UK II-25
Crookes Healthcare Launches Topical Ibuprofen Gel II-25
Dabur Introduces Antiseptic Cream and Backache Remedies II-25
Cadila Pharma Introduces Halonix II-25
Pharmacia Develops Bextra II-25
SSL International Launches Resolve Extra II-25
Warner Lambert Launches Calpol Children’s Analgesic II-25
Merck Sharp & Dohme Launches Vioxx II-25
Del Pharmaceuticals Introduces ArthriCare II-26
Pharmacia launches Celebrex II-26
Barr Laboratories Introduces Oxycodone II-26
Watson Introduces Norco Brand Hydrocodone Bitartrate and
Acetaminophen Pain Killers II-26
McNeil Consumer Healthcare Introduces Tylenol Sore Throat II-26
Boehringer Ingelheim Unveils Drug with Two Active Ingredients II-26
Johnson & Johnson/McNeil Introduces Tylenol for Women II-26
DRL Introduces Ibuprofen in US II-27
Omni Nutraceuticals Launches Four Versions of Patented Medicine II-27
SmithKline Beecham Launches 1,000-mg Crocin Tablets II-27
DRJ Extends STOPAIN Line II-27
Biomed Comm Launches Homeopathic Analgesic and Anti-
Inflammatory Products II-27
Reckitt Benckiser Launches Lemsip Analgesic and Decongestant II-28
DDD Launches Maximum Strength Ibuprofen Gel II-28
Johnson & Johnson Launches Narcotic Analgesic II-28
Win-Medicare Launches Urgendol II-28
US Dermatologics Launches Dura Patch Topical Analgesics II-28
Bayer Launches Combination Analgesic and Decongestant II-29
LifeTime Launches Extra Strength Version of Stopain Topical
Analgesic Spray II-29
Hyssop Launches Analgesic Balm II-29
Emami Launches External Analgesic II-29
Johnson & Johnson Launches Band-Aid External Analgesic and
Anti-Itch Spray II-29
Elan Obtains UK Marketing Rights for Ultiva II-29
Elan Pharma Launches Migramax II-29
SPIMACO Launches Fevadol Plus in Saudi Arabia II-29
California Energy Launches Ridopain, an External Analgesic
Spray II-30
McNeil Consumer Healthcare Launches Motrin Migraine II-30
Whitehall-Robins Healthcare Launches Advil Flu and Body Ache
Caplets II-30
McNeil Consumer Healthcare Launches Childrens Motrin Cold II-30

7. Recent Industry Activity II-31
Novartis Acquires Hexal Company and Major Stake in Eon Labs . II-31
NovaDel Pharma Receives Patent for Buccal Sprays Technology II-31
Nippon Shinyaku and Janssen Pharmaceutical to Develop and
Market Oral Analgesic II-31
Auxilium Pharmaceuticals Enters into a Licensing Agreement
with PharmaForm II-31
EC Sanctions Sale of Elan’s Prialt II-31
EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc II-32
Reckitt Benckiser plc Acquires Boots Healthcare
International II-32
Bayer Acquires Non-prescription Drug Business of Roche II-32
Industry Activity in Recent Past II-32
Bextra (Valdecoxib) Receives Green Signal from Health Canada II-32
Rhodia Announces Closure of Acetaminophen Plant in Louisiana II-33
NicOx Re-Gains Rights to CINOD from AstraZeneca II-33
Evotec Collaborates with Ionix II-33
Ethypharm and VIATRIS in Collaboration II-33
Rochem International Inc Signs Agreement with Juhua Group Corp II-33
NeoSan Signs an Agreement with Eli Lilly II-33
Shasun Chemicals & Drugs Ltd (India) Spins off Ibuprofen Unit II-33
American Home Products is Wyeth II-34
WhiteHall-Robins Assumes New Name II-34
Huzhou Konch Selects Rochem International II-34
Zydus Cadila Healthcare Receives Approval From UKMCA II-34
Rhodia Acquires Acetaminophen Business of BASF and Stake in
Wuxi Shahne Group (China) II-34
McNeil Consumer Healthcare Acquires St. Joseph 81- milligram
Adult Aspirin Brand II-34
Alpharma Acquires Two Brands of Ascent Pediatrics II-34
Johnson & Johnson Acquires Alza Corporation II-35
Abbott Laboratories Acquires BASF Pharma II-35
Terrell Announces a Partnership with Formulated Sciences II-35
Ohm Laboratories (India) Allies with Perrigo (US) II-35
3M Drug Delivery Inks an Agreement with Purdue Pharma II-35
GLAXO Hands Over Distribution Rights to SmithKline II-35
Pharmacia Corporation and Celltech in Agreement II-35
Albemarle Announces Capacity Expansion II-36
Ethypharm Expands French Site II-36
FDA Permits Ranbaxy Pharmaceuticals to Manufacture
Acetaminophen and Codeine Phosphate Tablets II-36
Dr Reddys Laboratories (India) Obtains USFDA Approval for
Ibuprofen tablets II-36
Dr. Reddy’s Receives FDA Approval to Market Oxaprozin II-36
Glaxo Merges with SmithKline Beecham II-36
Pfizer Buys Out Warner Lambert II-36
SHASUN Chemicals Joins Eastman Fine Company II-37
IGI Acquires Marketing and Distribution Rights from
Ethypharm (France) II-37
Bentley Pharmaceuticals Acquires Distribution Rights of
Codeisan II-37
FDA Permits Perrigo to Market and Manufacture Acetaminophen
Extended Release Tablets II-37
CeNeS Receives Approval to Market Moraxen (Morphine) II-37
Rnbaxy Obtains FDA Approval to Market Analgesics II-37

8. Focus on Select Key Players II-38
Bayer’s Consumer Care Division (USA) II-38
Bristol-Myers Squibb Co. (USA) II-38
Gelstat Corp (USA) II-38
Johnson & Johnson (USA) II-38
McNeil Consumer Healthcare (Canada) II-38
Naturopathic Laboratories International, Inc (USA) II-39
Novartis AG (Switzerland) II-39
Pfizer Inc. (USA) II-39
Reckitt Benckiser (UK) II-40
Taro Consumer Healthcare (USA) II-40
W. F. Young Inc (USA) II-40
Wyeth (USA) II-40
Wyeth Consumer Healthcare II-41

9. Global Market Perspective II-42
Table 2: World Recent Past, Current & Future Analysis for
Analgesics by Geographic Region/Country
US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-42

Table 3: World Historic Review for Analgesics by Geographic
Region/Country
US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-42

Table 4: World 20-Year Perspective for Analgesics by
Geographic Region/Country
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
1991, 1995, 2005 & 2010 (includes corresponding Graph/Chart) II-43

Table 5: World Recent Past, Current & Future Analysis for
Internal Analgesics by Geographic Region/Country
US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-44

Table 6: World Historic Review for Internal Analgesics by
Geographic Region/Country
US, Canada, Japan, Europe, Asia-
Pacific (excluding Japan), Latin America and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-44

Table 7: World 20-Year Perspective for Internal Analgesics by
Geographic Region/Country
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
1991, 1995, 2005 & 2010 (includes corresponding Graph/Chart) II-45

Table 8: World Recent Past, Current & Future Analysis for
Internal Analgesics by Product Segment
Aspirin,
Acetaminophen, Ibuprofen, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2001 through 2010 (includes corresponding Graph/Chart) II-46

Table 9: World Historic Review for Internal Analgesics by
Product Segment
Aspirin, Acetaminophen, Ibuprofen, and
Others Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-46

Table 10: World 20-Year Perspective for Internal Analgesics
by Product Segment
Percentage Breakdown of Dollar Sales for
Aspirin, Acetaminophen, Ibuprofen, and Others Markets for
Years 1991, 1995, 2005 & 2010 (includes corresponding Graph/
Chart) II-47

Table 11: World Recent Past, Current & Future Analysis for
Aspirin by Geographic Region/Country
US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-48

Table 12: World Historic Review for Aspirin by Geographic
Region/Country
US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-48

Table 13: World 20-Year Perspective for Aspirin by Geographic
Region/Country
Percentage Breakdown of Dollar Sales for US,
Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin
America and Rest of World Markets for Years 1991, 1995, 2005
& 2010 (includes corresponding Graph/Chart) II-49

Table 14: World Recent Past, Current & Future Analysis for
Acetaminophen by Geographic Region/Country
US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-50

Table 15: World Historic Review for Acetaminophen by
Geographic Region/Country
US, Canada, Japan, Europe, Asia-
Pacific (excluding Japan), Latin America and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-50

Table 16: World 20-Year Perspective for Acetaminophen by
Geographic Region/Country
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
1991, 1995, 2005 & 2010 (includes corresponding Graph/Chart) II-51

Table 17: World Recent Past, Current & Future Analysis for
Ibuprofen by Geographic Region/Country
US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-52

Table 18: World Historic Review for Ibuprofen by Geographic
Region/Country
US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-52

Table 19: World 20-Year Perspective for Ibuprofen by
Geographic Region/Country
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
1991, 1995, 2005 & 2010 (includes corresponding Graph/Chart) II-53

Table 20: World Recent Past, Current & Future Analysis for
Other Internal Analgesics by Geographic Region/Country
US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) II-54

Table 21: World Historic Review for Other Internal Analgesics
by Geographic Region/Country
US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-54

Table 22: World 20-Year Perspective for Other Internal
Analgesics by Geographic Region/Country
Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 1991, 1995, 2005 & 2010 (includes corresponding Graph/
Chart) II-55

Table 23: World Recent Past, Current & Future Analysis for
External Analgesics by Geographic Region/Country
US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-56

Table 24: World Historic Review for External Analgesics by
Geographic Region/Country
US, Canada, Japan, Europe, Asia-
Pacific (excluding Japan), Latin America and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-56

Table 25: World 20-Year Perspective for External Analgesics by
Geographic Region/Country
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
1991, 1995, 2005 & 2010 (includes corresponding Graph/Chart) II-57

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Historic Review III-1
Arthritis and Migraine: Common Ailments III-1
Competitive Scenario III-2
Table 26: Analgesics Market in the United States (2003-
2005E): Market Shares of Leading Players by value -
Johnson & Johnson, Wyeth, Bayer Group, Bristol-Myers
Squibb, GlaxoSmithKline, Chattem, Procter & Gamble, and
Others (includes corresponding Graph/Chart) III-2
Market Trends III-2
Internal Analgesics III-2
Cox-2 Drugs in for Some Trouble III-2
Switch to OTC Drugs III-3
Market Revival III-3
Table 27: Leading Brands of Oral Analgesics Tablets
(Internal) in the U.S. (2004&2005E): Market Share by
Value Sales for Tylenol, Advil, Aleve, Tylenol PM,
Bayer, Motrin IB, Excedrin, Tylenol Arthritis, Excedrin
Migraine, Ecotrin, and Private Label (includes
corresponding Graph/Chart) III-4

Table 28: US Analgesics Market (2004): Sales of Top 10
Internal Analgesics Brands in Supermarkets, and Drug &
Discount Stores (In US$ ‘000) III-5

Table 29: Leading Internal Analgesics Brands in the U.S.
Drugstores (2004&2005E): Market Share by Value Sales for
Advil, Tylenol, Aleve, Bayer, Tylenol PM, Motrin IB,
Tylenol Arthritis, Excedrin, Ecotrin, Excedrin Migraine,
and Others (includes corresponding Graph/Chart) III-5

Table 30: Leading Internal Analgesics Brands in the U.S.
Drugstores (2004&2005E): Market Share by Volume Sales
for Tylenol, Advil, Aleve, Bayer, Tylenol PM, Motrin IB,
St. Joseph, Tylenol Arthritis, Excedrin, Excedrin
Migraine, and Others (includes corresponding Graph/Chart) III-6

Table 31: Leading Brands of Internal Liquid Analgesics in
the U.S. (2004&2005E): Market Share by Value Sales for
Tylenol, Childrens Motrin, Infants Motrin, Childrens
Advil, Advil, and Private Label (includes corresponding
Graph/Chart) III-7

Table 32: Internal Analgesics Market in the U.S. By
Retail Channel (2004&2005E): Percentage Share by Value
Sales for Discount Stores, Food/Drug Combination Stores,
Chain Drug Stores, Supermarkets, and Independent Drug
Stores (includes corresponding Graph/Chart) III-7

Table 33: Market for Internal Liquid Analgesics in the
U.S. by Retail Channel (2004&2005E): Percentage Share by
Value Sales for Supermarkets, Drug Stores, and
Discounters (includes corresponding Graph/Chart) III-8
Popularity of Private Label Internal Analgesics Products
at U.S. Drug Stores: 2004 III-8
Promotional Strategies for the Internal Analgesics III-8
Pediatric Analgesics: The New Kid on the Block III-8
External Analgesics III-9
Stretching Boundaries III-9
Table 34: Leading Brands in the US External Analgesics
Market (2004&2005E): Percentage Share by Value Sales at
Drug Stores for Icy Hot, Bengay, Salonpas, Joint-Ritis,
Aspercreme, Super Strength Blue Emu, Absorbine Jr., Tiger
Balm, Capzasin HP, WellPatch, and Others (includes
corresponding Graph/Chart) III-9

Table 35: External Analgesics Market in the U.S. By
Retail Channel (2004&2005E): Percentage Share by Value
Sales for Chain drug stores, Discount stores, Food/drug
combination stores, Independent drug stores, and
Supermarkets (includes corresponding Graph/Chart) III-10
Rubs, Patches: Driving the External Analgesics Market III-10
Patch Relief Gaining Momentum III-10
Retail Market in Recent Past III-11
Retail Scenario III-11
Table 36: Analgesics Market in the U.S. By Retail Channel
(2004): Percentage Share of Drugstores, Food stores, and
Mass-merchandisers (includes corresponding Graph/Chart) III-11

Table 37: Analgesics Market in the U.S. By Segments in
Independent Drugstores (2004): Percentage Share of Adult
internal analgesics, External analgesics, Pain and fever
relief for Children, and Motion sickness, sleep aids, and
stimulants (includes corresponding Graph/Chart) III-12
Leading Analgesic Drugs for Moderate to Severe Pain in
the U.S III-12
New Product Introductions in Internal and External
Analgesics in 2004 III-12
Market in Recent Past III-13
Table 38: Capacity Breakdown of Acetaminophen By Company:
2002 (In metric tons per annum) III-13
Product Innovations/Introductions III-13
Product Innovations/Introductions in Recent Past III-14
Strategic Corporate Developments III-19
Strategic Corporate Developments in Recent Past III-20
Major Players III-22
B.Market Analytics III-24
Table 39: US Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-24

Table 40: US Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-25

Table 41: US 20-Year Perspective for Analgesics by Product
Segment
Percentage Breakdown of Dollar Sales for Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets for 1991, 1995, 2005 & 2010
(includes corresponding Graph/Chart) III-25

2. Canada III-26
A.Market Analysis III-26
Current and Future Analysis III-26
Historic Review III-26
An Overview of Pharmaceutical Prescriptions Market III-26
Table 42: Canadian Pharmaceuticals Market (2004):
Prescriptions Dispensed at Retail Level (In $ billion)
(includes corresponding Graph/Chart) III-26

Table 43: Major Pharmaceutical Firms in Canada (2004E):
Sales in $ Millions III-27
McNeil Consumer Healthcare
A Major Player III-27
Leading Brands in the Canadian Analgesics Market III-28
Table 44: Popular Brands of Pain & Inflammation
Medication in North America (2004): Percentage Share of
Advil, Tylenol, Motrin, Aleve, Celebre, Vioxx, Aspirin,
Ibuprofen, Naprosyn, and Bextra (includes corresponding
Graph/Chart) III-28
Strategic Corporate Developments in Recent Past III-28
B.Market Analytics III-29
Table 45: Canadian Recent Past, Current & Future Analysis
for Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-29

Table 46: Canadian Historic Review for Analgesics by
Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-29

Table 47: Canadian 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-30

3. Japan III-31
A.Market Analysis III-31
Current and Future Analysis III-31
Historic Review III-31
Competitive Scenario III-31
Table 48: OTC Analgesics Market in Japan (2004- 2005E):
Market Shares of Leading Players by Value (Shipments) -
Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical,
Shionogi, and Others (includes corresponding Graph/Chart) III-31
Strategic Corporate Developments III-32
B.Market Analytics III-32
Table 49: Japanese Recent Past, Current & Future Analysis
for Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-32

Table 50: Japanese Historic Review for Analgesics by
Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-33

Table 51: Japanese 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-33

4. Europe III-34
A.Market Analysis III-34
Current and Future Analysis III-34
By Region III-34
By Product Group/Segment III-34
Historic Review III-34
The European Pain Management Market III-34
Generics Affect the Market III-35
Table 52: Popular Brands of Pain & InflammationMedication
in Europe (2004): Percentage Share of Aspirin, Voltaren,
Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin,
and Paracetamol (includes corresponding Graph/Chart) III-35
B.Market Analytics III-36
Table 53: European Recent Past, Current & Future Analysis
for Analgesics by Geographic Region/Country
France,
Germany, UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-36

Table 54: European Recent Past, Current & Future Analysis
for Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-36

Table 55: European Historic Review for Analgesics by
Geographic Region/Country
France, Germany, UK, Italy,
Spain, Russia and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
1991 through 2000 (includes corresponding Graph/Chart) III-37

Table 56: European Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-37

Table 57: European 20-Year Perspective for Analgesics by
Geographic Region/Country
Percentage Breakdown of Dollar
Sales for France, Germany, UK, Italy, Spain, Russia and Rest
of Europe Markets for Years 1991, 1995, 2005 & 2010
(includes corresponding Graph/Chart) III-38

Table 58: European 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for Years 1991,
1995, 2005 & 2010 (includes corresponding Graph/Chart) III-39

4a. France III-40
A.Market Analysis III-40
Current and Future Analysis III-40
Historic Review III-40
Competitive Scenario III-40
Table 59: Analgesics Market in France (2004&2005E): Market
Shares of Leading Players by Value
Bristol-Myers Squibb,
Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare,
Boots Healthcare, GlaxoSmithKline, Boehringer Ingelheim,
and Others (includes corresponding Graph/Chart) III-40
Leading Brands in the French Analgesics Market III-41
Product Innovations/Introductions in Recent Past III-41
Strategic Corporate Developments in Recent Past III-41
B.Market Analytics III-42
Table 60: French Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-42

Table 61: French Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-43

Table 62: French 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-43

4b. Germany III-44
A.Market Analysis III-44
Current and Future Analysis III-44
Historic Review III-44
Competitive Scenario III-44
Table 63: Analgesics Market in Germany(2004&2005E): Market
Shares of Leading Players by Value
Bayer Group,
Boehringer Ingelheim, Wyeth Consumer Healthcare, and
Others (includes corresponding Graph/Chart) III-44
Leading Brands in the German Analgesics Market III-45
B.Market Analytics III-46
Table 64: German Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) III-46

Table 65: German Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-46

Table 66: German 20-Year Perspective for Analgesics by Product
Segment
Percentage Breakdown of Dollar Sales for Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and
External Analgesics Markets for 1991, 1995, 2005 & 2010
(includes corresponding Graph/Chart) III-47

4c. The United Kingdom III-48
A.Market Analysis III-48
Current and Future Analysis III-48
Historic Review III-48
The Pharmaceutical Market III-48
The UK Government: Changing Tactics III-48
External Analgesics Market: All Set to Conquer III-49
Reckitt Benckiser
A Major Player III-49
Leading Products III-49
Competitive Scenario III-50
Table 67: Analgesics Market in the United Kingdom (2004&
2005E): Market Shares of Leading Players by Value
Boots
Healthcare, GlaxoSmithKline, Roche, Novartis, Wyeth
Consumer Healthcare, Private Labeland Others (includes
corresponding Graph/Chart) III-50
Leading Brands in the UK Analgesics Market III-50
Ten Leading Analgesics Brands for Children in the UK
Analgesics Market III-51
Recent Industry Activity III-52
Product Innovations/Introductions in Recent Past III-52
B.Market Analytics III-53
Table 68: UK Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-53

Table 69: UK Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-54

Table 70: UK 20-Year Perspective for Analgesics by Product
Segment
Percentage Breakdown of Dollar Sales for Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets for 1991, 1995, 2005 & 2010
(includes corresponding Graph/Chart) III-54

4d. Italy III-55
A.Market Analysis III-55
Current and Future Analysis III-55
Historic Review III-55
Competitive Scenario III-55
Table 71: Analgesics Market in Italy (2004&2005E): Market
Shares of Leading Players by Value
Bayer Group,
Angelini, Novartis, Bristol-Myers Squibb, Boots
Healthcare, and Others (includes corresponding Graph/
Chart) III-55
Leading Brands in the Italian Analgesics Market III-56
B.Market Analytics III-56
Table 72: Italian Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-56

Table 73: Italian Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-57

Table 74: Italian 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-57

4e. Spain III-58
A.Market Analysis III-58
Current and Future Analysis III-58
Historic Review III-58
Competitive Scenario III-58
Table 75: Analgesics Market in Spain (2004&2005E): Market
Shares of Leading Players by Value
Bayer Group,
Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots
Healthcare, and Others (includes corresponding Graph/
Chart) III-58
Leading Brands in the Spanish Analgesics Market III-59
B.Market Analytics III-59
Table 76: Spanish Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-59

Table 77: Spanish Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-60

Table 78: Spanish 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-60

4f. Russia III-61
A.Market Analysis III-61
Current and Future Analysis III-61
Historic Review III-61
Leading Brands in the Russian Analgesics Market III-61
B.Market Analytics III-62
Table 79: Russian Recent Past, Current & Future Analysis for
Analgesics by Product Segment
Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-62

Table 80: Russian Historic Review for Analgesics by Product
Segment
Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) III-62

Table 81: Russian 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995, 2005
& 2010 (includes corresponding Graph/Chart) III-63

4g. Rest of Europe III-64
A.Market Analysis III-64
Current and Future Analysis III-64
Historic Review III-64
Leading Brands in the Analgesics Market in Rest of Europe III-64
Product Innovations/Introductions III-71
Product Innovations/Introductions in Recent Past III-71
Strategic Corporate Developments III-71
B.Market Analytics III-72
Table 82: Rest of Europe Recent Past, Current & Future
Analysis for Analgesics by Product Segment
Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) III-72

Table 83: Rest of Europe Historic Review for Analgesics by
Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-73

Table 84: Rest of Europe 20-Year Perspective for Analgesics
by Product Segment
Percentage Breakdown of Dollar Sales
for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
and Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-73

5. Asia-Pacific III-74
A.Market Analysis III-74
Current and Future Analysis III-74
Historic Review III-74
The OTC Analgesic Market III-74
OTC Analgesics Market in Asia-Pacific (2004): A
Comparative Analysis of the Major Regions
Australia,
China and South Korea III-75
Aspirin
The Chinese Market III-75
Analgesics Market in India III-75
Unique NSAID Combinations Offered in India III-75
Prices of NSAID Combinations or Single Drugs in India (In
Rs per tablet) III-76
Leading Brands in the Analgesics Market in Asia-Pacific III-76
Product Innovations/Introductions in Recent Past III-80
Strategic Corporate Developments in Recent Past III-81
B.Market Analytics III-83
Table 85: Asia-Pacific Recent Past, Current & Future
Analysis for Analgesics by Product Segment
Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) III-83

Table 86: Asia-Pacific Historic Review for Analgesics by
Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-83

Table 87: Asia-Pacific 20-Year Perspective for Analgesics by
Product Segment
Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 1991, 1995, 2005
& 2010 (includes corresponding Graph/Chart) III-84

6. Latin America III-85
A.Market Analysis III-85
Current and Future Analysis III-85
Historic Review III-85
Leading Brands in the Analgesics Market in Latin America III-85
B.Market Analytics III-89
Table 88: Latin American Recent Past, Current & Future
Analysis for Analgesics by Product Segment
Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) III-89

Table 89: Latin American Historic Review for Analgesics by
Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-89

Table 90: Latin American 20-Year Perspective for Analgesics
by Product Segment
Percentage Breakdown of Dollar Sales
for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
and Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-90

7. Rest of World III-91
Market Analysis III-91
Current and Future Analysis III-91
Historic Review III-91
Table 91: Rest of World Recent Past, Current & Future
Analysis for Analgesics by Product Segment
Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) III-92

Table 92: Rest of World Historic Review for Analgesics by
Product Segment
Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-92

Table 93: Rest of World 20-Year Perspective for Analgesics
by Product Segment
Percentage Breakdown of Dollar Sales
for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
and Others) and External Analgesics Markets for 1991, 1995,
2005 & 2010 (includes corresponding Graph/Chart) III-93
IV. COMPETITION
1. 3M Company (USA) IV-1
Table 94: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ billion) IV-4

Table 95: Half Yearly Sales Analysis by Business
Segment: 2004-2005 (H1) (In US$ billion) IV-5

Table 96: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-5

Table 97: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ billion) IV-5

Table 98: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ billion) IV-6

Table 99: Quarterly Sales Analysis: 2003-2004 (In US$
billion) IV-6
3M Espana SA (Spain) IV-19
3M New Zealand Ltd. (New Zealand) IV-22
3M Pharmaceuticals Pty., Ltd. (Australia) IV-22
2. 999 Group (China) IV-23
3. Abbott Laboratories (USA) IV-24
Table 100: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-26

Table 101: Half Yearly Sales Analysis by Segment: 2004
-2005 (H1) (In US$ million) IV-27

Table 102: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-27

Table 103: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-27

Table 104: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-28
4. Able Laboratories, Inc. (USA) IV-50
5. Albemarle Corporation (USA) IV-51
6. Alembic Ltd. (India) IV-55
7. Aliachem Benelux BV (The Netherlands) IV-57
8. Alpharma US Pharmaceuticals (USA) IV-58
9. Altana Pharma AG (Germany) IV-61
10. Anhui Xinli Pharmaceutical Co., Ltd. (China) IV-62
11. Anshan Xianzhen Pharmaceutical Co., Ltd. (China) IV-63
12. Apoteket AB (Sweden) IV-63
13. AstraZeneca PLC (UK) IV-64
Table 105: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ billion) IV-66
Table 106: First Quarter Sales Analysis by Geographic
Region: 2004-2005 (Q1) (In US$ billion) IV-67
Table 107: Annual Sales Analysis by Therapy Area: 2003
-2004 (In US$ billion) IV-67

Table 108: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ billion) IV-67
AstraZeneca PLC (UK) IV-76
AstraZeneca Pty., Ltd. (Australia) IV-76
14. Athenstaedt GmbH + Co. KG (Germany) IV-78
15. Atos Pharmaceuticals & Medical Herbs (Egypt) IV-79
16. AWD Pharma GmbH and Co. KG (Dresden) IV-79
17. Bard Pharmaceuticals Ltd. (UK) IV-80
18. Barr Laboratories, Inc. (USA) IV-81
19. Bayer AG (Germany) IV-83
Table 109: First Quarter Sales Analysis: 2004-2005 (Q1)
(In € million) IV-85

Table 110: Annual Sales Analysis: 2003-2004 (In €
million) IV-85

Table 111: Annual Sales Analysis by Segment: 2003-2004
(In € million) IV-86

Table 112: Annual Sales Analysis by Geographical
Region: 2003-2004 (In € million) IV-86

Table 113: Annual Sales Analysis by Product: 2003-2004
(In € million) IV-86
Bayer Consumer Care Division (USA) IV-94
Bayer Corporation (USA) IV-95
Bayer Health Care Ltd. (Australia) IV-99
Bayer Pharmaceutical Division (USA) IV-101
Bayer Pharmaceuticals (Australia) IV-103
Bayer SpA (Italy) IV-104
20. Beijing Baoshutang Pharmaceutical Co., Ltd. (China) IV-105
21. Beijing Shuangqiao Pharmaceutical Co. (China) IV-105
22. Beijing Shuguang Pharmaceutical Co., Ltd. (China) IV-105
23. Beijing United Pharmaceutical Co., Ltd. (China) IV-106
24. Beijing Wanhui Pharmaceutical Group (China) IV-106
25. Beijing Zizhu Pharmaceutical Co., Ltd. (China) IV-107
26. Belupo Doo (Croatia) IV-108
27. Berlin-Chemie AG (Germany) IV-109
28. Betapharm Arzneimittel GmbH (Germany) IV-110
29. Biological E. Ltd. (India) IV-113
30. Biologische Heilmittel Heel GmbH (Germany) IV-116
31. Boehringer Ingelheim GmbH (Germany) IV-118
Table 114: Annual Sales Analysis: 2003-2004 (In €
million) IV-118

Table 115: Annual Sales Analysis by Product Segment:
2003-2004 (In € million) IV-118

Table 116: Annual Sales Analysis by Region: 2003-2004
(In € million) IV-119
Boehringer Ingelheim France (Paris) IV-123
Boehringer Ingelheim Italia SpA (Italy) IV-124
Boehringer Ingelheim Pharma KG (Germany) IV-125
Boehringer Ingelheim Pharmaceuticals, Inc. (USA) IV-129
32. Boots Group PLC (The) (UK) IV-130
33. Bristol-Myers Squibb Co. (USA) IV-132
Table 117: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-134

Table 118: Annual Sales Analysis by Segment: 2003-2004
(In US$ billion) IV-134

Table 119: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ billion) IV-134
Bristol Myers SA (Spain) IV-145
Bristol Myers Squibb (France) IV-145
Bristol Myers Squibb Egypt (Egypt) IV-146
Bristol-Myers Squibb Australia Pty., Ltd. (Australia) IV-146
34. C P Pharmaceuticals Ltd. (UK) IV-147
35. Cambrex Profarmaco Milano Srl (Italy) IV-148
36. Center Laboratories, Inc. (Taiwan) IV-148
37. Central Pharmacal Co., Ltd. (The) (Taiwan) IV-148
38. Chang An Chemical Ind Co., Ltd. (Taiwan) IV-149
39. Changchun Daxing Pharmaceutical Co., Ltd. (China) IV-149
40. Chattem, Inc. (USA) IV-150
Table 120: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ million) IV-151
Table 121: First Quarter Sales Comparison by Business
Segment: 2004-2005 (Q1) (In US$ million) IV-151
Table 122: First Quarter Sales Analysis By Geographical
Region: 2004-2005 (Q1) (In US$ million) IV-152
Table 123: Annual Sales Analysis: 2003-2004 (In US$
million) IV-152

Table 124: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ million) IV-152

Table 125: Annual Sales Analysis By Geographical
Region: 2003-2004 (In US$ million) IV-152

Table 126: Quarterly Sales Comparison: 2003-2004 (In
US$ million) IV-153
41. Chemferm Industrial Pharmaceuticals SA (Spain) IV-155
42. Cheng Fong Chemical Co., Ltd. (Taiwan) IV-155
43. Chengdu Pharmaceutical Corporation (China) IV-155
44. Chiesi Farmaceutici SpA (Italy) IV-156
45. Chifeng Pharmaceutical Group Co., Ltd. (China) IV-157
46. Chongqing Daxin Pharmaceutical Co., Ltd. (China) IV-158
47. Chongqing Dikang Changjiang Pharmaceutical Co., Ltd.
(China) IV-158
48. Clonmel Healthcare Ltd. (Ireland) IV-159
49. Clover Corporation Limited (Australia) IV-160
50. Codal Synto Ltd. (Cyprus) IV-161
51. Crookes Healthcare (UK) IV-162
52. Cullen & Davison Ltd. (Ireland) IV-163
53. Daewoong Pharm Co., Ltd (Korea) IV-164
54. Del Laboratories, Inc. (USA) IV-165
Table 127: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ million) IV-166
55. Dompé Farmaceutici SpA (Italy) IV-169
56. Douglas Pharmaceuticals Ltd. (New Zealand) IV-170
57. Dr. Reddys Laboratories Ltd. (India) IV-171
58. DRJ Group, Inc. (USA) IV-175
59. Elan Corporation PLC (Ireland) IV-176
60. Eli Lilly and Company (USA) IV-178
Table 128: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-180

Table 129: Half Yearly Sales Analysis by Segment: 2004
-2005 (H1) (In US$ million) IV-180

Table 130: Half Yearly Sales Analysis by Product: 2004
-2005 (H1) (In US$ million) IV-180

Table 131: Annual Sales Analysis: 2002-2004 (In US$
million) IV-181

Table 132: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-181

Table 133: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-182

Table 134: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-182

Table 135: Annual Sales Analysis by Region: 2003-2004
(In US$ million) IV-182
61. Eli Lilly And Company Limited (UK) IV-191
Eli Lilly Egypt (Egypt) IV-191
62. Elite Pharmaceuticals, Inc. (USA) IV-192
63. Endo Pharmaceuticals Holdings, Inc. (USA) IV-193
64. F. Hoffmann-La Roche Ltd. (Switzerland) IV-196
Table 136: Annual Sales Analysis: 2003-2004 (In CHF
billion) IV-197

Table 137: Annual Sales Analysis by Segment: 2003-2004
(In CHF billion) IV-197

Table 138: Annual Sales Analysis by Geographical
Region: 2003-2004 (In CHF billion) IV-198
Roche Ireland Limited (Ireland) IV-202
Roche Products, Ltd. (UK) IV-203
Roche SpA (Italy) IV-204
65. Farmaco SA (Moldova) IV-205
66. Farmades SpA (Italy) IV-205
67. Farmina Sp. z o.o. (Poland) IV-206
68. Foliapharm Gesundheitspflege und Arbeitshygiene GmbH
(Germany) IV-206
69. Fuzhou Fuxing Pharmaceutical Co., Ltd. (China) IV-207
70. Galenika A.D. (Yugoslavia) IV-210
71. Gelstat Corporation (USA) IV-213
Table 139: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-213
72. Generics [UK] Limited (UK) IV-214
73. GlaxoSmithKline PLC (UK) IV-215
Table 140: Half Yearly Sales Analysis: 2004-2005 (H1)
(In £ million) IV-216

Table 141: Half Yearly Sales Analysis by Division:
2004-2005 (H1) (In £ million) IV-216

Table 142: Annual Sales Analysis: 2003-2004 (In £
million) IV-216

Table 143: Annual Sales Analysis by Division: 2003-2004
(In £ million) IV-216
Glaxo SmithKline Consumer Healthcare (USA) IV-227
Glaxosmithkline (Dungarvan) Ltd. (Ireland) IV-227
Glaxosmithkline (Thailand) Ltd. (Thailand) IV-228
GlaxoSmithKline Pte., Ltd. (Singapore) IV-228
74. Global Pharmaceutical Industries (Egypt) IV-229
75. Gödecke GmbH (Germany) IV-229
76. Grunenthal GmbH (Germany) IV-229
77. Guangzhou Dongkang Pharmaceutical Co., Ltd. (China) IV-230
78. Hainan Sanye Pharmaceutical Co., Ltd. (China) IV-230
79. Hainan Xipu Pharmaceutical Co., Ltd. (China) IV-230
80. Hakim Pharmaceutical (Iran) IV-231
81. Heilongjiang Huaxing Pharmaceutical Co., Ltd. (China) IV-233
82. Heilongjiang Jiren Pharmaceutical Co., Ltd. (China) IV-233
83. Heinrich Mack Nachf. GmbH & Co. KG (Germany) IV-233
84. Helsinn Birex Pharmaceuticals Ltd (China) IV-234
85. Henan Huazhong Pharmaceutical Group Corporation (China) IV-234
86. Henan Xinxiang Pharmaceutical Co., Ltd. (China) IV-234
87. Herron Pharmaceuticals (Australia) IV-235
88. Hsin-Kung Pharmaceutical Co., Ltd. (Taiwan) IV-236
89. Hunan Pharmaceutical Co., Ltd. (China) IV-237
90. Il Yang Pharm Co., Ltd , (Korea) IV-238
91. Ildong Pharm Co., Ltd. (Korea) IV-240
92. Iran Daru Co. (Iran) IV-253
93. Ivax Pharmaceuticals Uk, Ltd (UK). IV-255
Ivax Ireland (Ireland) IV-256
94. Jiamusi Luling Pharmaceutical Co., Ltd. (China) IV-257
95. Jian Yisheng Pharmaceutical Co., Ltd. (China) IV-257
96. Jiangsu Diyi Pharmaceutical Co., Ltd. (China) IV-258
97. Jiangsu Huatai Antibiotic Co., Ltd. (China) IV-258
98. Jiaozuo Kangli Pharmaceutical Co., Ltd. (China) IV-259
99. Jinzhou Huaqing Pharmaceutical Co., Ltd. (China) IV-259
100. Johnson & Johnson (USA) IV-260
Table 144: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ billion) IV-262

Table 145: First Quarter Sales Analysis By Segment:
2004-2005 (Q1) (In US$ billion) IV-262
Table 146: First Quarter Sales Analysis By Geographic
Region: 2004-2005 (Q1) (In US$ billion) IV-262
Table 147: Annual Sales Analysis: 2002-2004 (In US$
billion) IV-262

Table 148: Annual Sales Analysis By Segment: 2003-2004
(In US$ billion) IV-263

Table 149: Annual Sales Analysis By Geographic Region:
2003-2004 (In US$ billion) IV-263

Table 150: Quarterly Sales Comparison: 2003-2004 (In
US$ billion) IV-263
Janssen
Cilag, SpA (Italy) IV-271
Johnson & Johnson Consumer Products, Inc. (USA) IV-271
Janssen Pharmaceutica Products, LP (USA) IV-273
Johnson & Johnson (Pty) Ltd. (South Africa) IV-274
Mcneil Consumer Healthcare (Canada) IV-275
Ortho-Mcneil Pharmaceutical, Inc. (USA) IV-275
Tasmanian Alkaloids Pty Ltd. (Australia) IV-277
101. Kunming Kangfu Pharmaceutical Co., Ltd. (China) IV-278
102. Kwangdong Pharmaceutical Co., Ltd. (Korea) IV-278
103. Laboratoires Pharmaceutiques Trenker SA (Belgium) IV-279
104. Laboratori Guidotti, SpA (Italy) IV-282
105. Leiner Health Products, Inc. (USA) IV-284
106. Lion Corporation (Japan) IV-286
Table 151: Annual Sales Analysis: 2003-2004 (In ¥
million) IV-289

Table 152: Annual Sales Analysis by Segment: 2003-2004
(In ¥ million) IV-289
107. Luoyang Minsheng Pharmaceutical Co., Ltd. (China) IV-295
108. Maxima Medical Ltd. (Israel) IV-295
109. Mayne Group Limited (Australia) IV-296
Table 153: Annual Sales Comparison: 2003-2004 (In AUS$
million) IV-298

Table 154: Annual Sales Comparison by Business Segment:
2003-2004 (In AUS$ million) IV-299
Table 155: Annual Sales Comparison by Geographical
Region: 2003-2004 (In AUS$ million) IV-299
Mayne Pharma Pty., Ltd. (Australia) IV-303
110. Medicis Pharmaceutical Corporation (USA) IV-304
111. Medosan Ricerca, SRL (Italy) IV-305
112. Merck & Co., Inc. (USA) IV-306
Table 156: Annual Sales Comparison: 2002-2004 (In US$
Million) IV-307

Table 157: Annual Sales Comparison by Product Segment:
2003-2004 (In US$ Million) IV-307

Table 158: Quarterly Sales Comparison: 2003-2004 (In
US$ Million) IV-307
Merck Ltd. (India) IV-311
Table 159: First Quarter Sales Analysis: 2004-2005 (Q1)
(In INR million) IV-312

Table 160: First Quarter Sales Analysis by Segment:
2004-2005 (Q1) (In INR million) IV-312

Table 161: Annual Sales Analysis: 2003-2004 (In INR
million) IV-312

Table 162: Annual Sales Analysis by Segment: 2003-2004
(In INR million) IV-312
113. Mey See Pharmaceutical Co., Ltd. (Taiwan) IV-313
114. Milani Leonardo, SRL (Italy) IV-313
115. Molimin Arzneimittel GmbH (Germany) IV-313
116. Montefarmaco, SpA (Italy) IV-314
117. Nang Kuang Pharmaceutical Co., Ltd. (Taiwan) IV-315
118. Nanjing Laoshan Pharmaceutical Co., Ltd. (China) IV-317
119. Napp Pharmaceuticals Ltd. (UK) IV-318
120. Nasr Pharmaceutical & Mfg. (Iran) IV-318
121. Naturopathic Laboratories International, Inc. (USA) IV-319
122. Nile Pharmaceuticals & Chemical Industries (Egypt) IV-319
123. Norma Hellas SA (Greece) IV-320
124. North China Pharmaceutical Corporation (China) IV-321
125. Novartis AG (Switzerland) IV-322
Table 163: Annual Sales Analysis: 2003-2004 (In US$
million) IV-325

Table 164: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-325

Table 165: Annual Sales by Geographical Region: 2003-
2004 (In US$ million) IV-325

Table 166: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-326
Novartis Farma SpA (Italy) IV-339
Novartis Farmaceutica S.A. (Spain) IV-340
Novartis Pharma (Egypt) IV-341
126. Omni Nutraceuticals, Inc. (USA) IV-342
127. Perrigo Company (USA) IV-343
Table 167: Annual Sales Analysis: 2003-2005 (In US$
million) IV-344

Table 168: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-345

Table 169: Annual Sales Analysis by Product Category:
2003-2004 (In US$ million) IV-345

Table 170: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-345
128. Pfizer, Inc. (USA) IV-349
Table 171: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ billion) IV-351

Table 172: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-351

Table 173: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ billion) IV-351

Table 174: Annual Sales Analysis by Geographical
Region: 2003-2004 (In US$ billion) IV-351

Table 175: Quarterly Sales Analysis: 2003-2004 (In US$
billion) IV-352
Pfizer Consumer Healthcare (Australia) IV-364
Pfizer Egypt SAE (Egypt) IV-365
Pfizer Hellas SA (Greece) IV-365
Pfizer Pty., Ltd. (Australia) IV-366
129. Pharma-Cosme (Pvt) Ltd. (Sri Lanka) IV-368
130. Pierre Fabre Santi (France) IV-368
131. Polfarmex SA (Poland) IV-369
132. Prudue Pharma L.P (USA). IV-370
133. Qingyuan Xinbeijiang Pharmaceutical Co., Ltd. (China) IV-371
134. Ranbaxy Laboratories Ltd. (India) IV-372
Table 176: First Quarter Sales Analysis: 2004-2005 (Q1)
(In INR billion) IV-379

Table 177: Annual Sales Analysis: 2003-2004 (In INR
billion) IV-379
Ranbaxy Ireland, Ltd. (Ireland) IV-389
Ranbaxy Pharmaceuticals, Inc. (USA) IV-390
135. Razak Laboratories (Iran) IV-392
136. Reckitt Benckiser PLC (UK) IV-393
Table 178: Annual Sales Analysis: 2003-2004 (In £
million) IV-394

Table 179: Annual Sales Analysis by Product Segment:
2003-2004 (In £ million) IV-394

Table 180: Annual Sales Analysis by Geographical
Region: 2003-2004 (In £ million) IV-394
Reckitt Benckiser India, Ltd. (India) IV-395
137. Recordati SpA (Italy) IV-396
138. Rhodia SA (France) IV-400
Table 181: Half Yearly Sales Analysis: 2004-2005 (H1)
(In € million) IV-403

Table 182: Annual Sales Analysis: 2003-2004 (In €
million) IV-403

Table 183: Quarterly Sales Analysis: 2003-2004 (In €
billion) IV-403
139. Rowa Pharmaceuticals, Ltd. (Ireland) IV-408
140. Sanofi-Aventis (France) IV-409
Table 184: Half Yearly Sales Analysis: 2004-2005 (H1)
(In € million) IV-410

Table 185: Half Yearly Sales Analysis by Segment: 2004
-2005 (H1) (In € million) IV-410

Table 186: Half Yearly Sales Analysis by Product: 2004
-2005 (H1) (In € million) IV-410
141. Schering-Plough Corporation (USA) IV-415
Table 187: First Quarter Sales Analysis by Segments:
2004-2005 (Q1) (US$ million) IV-417

Table 188: First Quarter Sales Analysis by Regions:
2004-2005 (Q1) (US$ million) IV-417

Table 189: Annual Sales Analysis by Segments: 2003-2004
(US$ million) IV-417

Table 190: Annual Sales Analysis by Regions: 2003-2004
(US$ million) IV-417
142. Shandong Ruiyang Pharmaceutical Co., Ltd. (China) IV-428
143. Shandong Xinhua Pharmaceutical Co, Ltd. (China) IV-429
144. Shanghai Fosun Industrial Co., Ltd. (China) IV-430
145. Shanghai Sanwei Pharmaceutical Co., Ltd. (China) IV-431
146. Shanghai Siyao Co., Ltd. (China) IV-431
147. Shanghai Wuzhou Pharmaceutical Co., Ltd. (China) IV-432
148. Shanxi Ruifeng Pharmaceutical Co., Ltd. (China) IV-432
149. Shenzhen Gosun Pharmaceutical Co., Ltd. (China) IV-433
150. Shenzhen Tongan Pharmaceutical Co., Ltd. (China) IV-434
151. Shin poong pharmaceutical co. Ltd (Korea). IV-435
152. Shinlon Pharmaceutical Ind Co., Ltd. (Taiwan) IV-436
153. Sichuan Chuantou Pharmaceutical Co., Ltd. (China) IV-436
154. Sichuan Pharmaceutical Shareholding Co., Ltd. (China) IV-437
155. Sigma (Pharmaceutical) Pty., Ltd. (Australia) IV-438
Table 191: Annual Sales Comparison: 2003-2004 (In A$
billion) IV-438
156. Sino-America Shanghai Squibb Pharmaceuticals Ltd. (China) IV-439
157. Southwest Synthetic Pharmaceutical Corp. Ltd . (China) IV-440
158. SSL International PLC (UK) IV-441
159. Taejoon Pharmaceutical Co., Ltd. (Korea) IV-444
160. Tainan Peng Lai Ent Co., Ltd. (Taiwan) IV-445
161. Taiwan Tanabe Seiyaku Co. Ltd. (Taiwan) IV-445
162. Taro Consumer Healthcare (USA) IV-446
163. Teva Pharmaceutical Industries Ltd. (Israel) IV-447
Table 192: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ Million) IV-448
Table 193: Half Yearly Sales Analysis by Geographic
Region: 2004-2005 (H1) (In US$ Million) IV-449
Table 194: Half Yearly Sales Analysis by Business
Segment: 2004-2005 (H1) (In US$ Million) IV-449

Table 195: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ Million) IV-449
Table 196: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ Million) IV-449
164. The Mentholatum Company, Inc. (USA) IV-456
165. Thornton & Ross Ltd. (UK) IV-457
166. Tianjin Aikang Medical Health Products Co. (China) IV-457
167. Tianjin Lisheng Pharmaceutical Co. Ltd. (China) IV-458
168. UCB S.A. (Belgium) IV-459
169. Uni-Pharma S.A. (Greece) IV-461
170. Vitamed Pharmaceutical Industries Ltd.
171. Vramed Jsc (Bulgaria) IV-461
172. Vramed Jsc (Bulgaria) IV-462
173. W. F. Young, Inc. (USA) IV-463
174. Wanhe Pharmercuetical Co., Ltd. (China) IV-465
175. Weleda Ltd . (UK) IV-465
176. Wockhardt Limited (India) IV-466
177. Wuhan Pharmaceutical Co., Ltd. (China) IV-467
178. Wyeth (USA) IV-468
Table 197: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ million) IV-469

Table 198: First Quarter Sales Analysis by Segment:
2004-2005 (In US$ million) IV-470

Table 199: Annual Sales Analysis: 2003-2004 (In US$
million) IV-470

Table 200: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-470

Table 201: Annual Sales Analysis by Region: 2003-2004
(In US$ million) IV-470

Table 202: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-471

Table 203: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-472
Wyeth Medica Ireland (USA) IV-477
179. Xinxiang Zuojinming Pharmaceutical Co., Ltd. (China) IV-478
180. YF Chemical Corporation (Taiwan) IV-478
181. Zentiva Group (Czech Republic) IV-479
182. Zhangjiakou Pharmaceutical Group Corporation (China) IV-481
183. Zhejiang Taikang Pharmaceutical Co., Ltd. (China) IV-481
184. Zhejiang Yuezhou Pharmaceutical Co., Ltd. (China) IV-482
185. Zhengzhou Yuxin Pharmaceutical Co., Ltd. (China) IV-482
186. Zhuhai Sez Lizhu Pharmaceutical Group Co., Ltd. (China) IV-482